GSK plc – NYSE:GSK
GSK stock price today
$39.306
+5.22
+15.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
GSK stock price monthly change
-12.97%
month
GSK stock price quarterly change
-12.97%
quarter
GSK stock price yearly change
-8.14%
year
GSK key metrics
Market Cap | 68.72B |
Enterprise value | 68.15B |
P/E | 44.03 |
EV/Sales | 2.17 |
EV/EBITDA | 7.53 |
Price/Sales | 1.76 |
Price/Book | 7.89 |
PEG ratio | 16.24 |
EPS | 1.10 |
Revenue | 30.74B |
EBITDA | 9.93B |
Income | 4.48B |
Revenue Q/Q | 5.92% |
Revenue Y/Y | 5.69% |
Profit margin | 8.02% |
Oper. margin | 16.64% |
Gross margin | 72.05% |
EBIT margin | 16.64% |
EBITDA margin | 32.33% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGSK stock price history
GSK stock forecast
GSK financial statements
| Jun 2023 | 7.17B | 1.62B | 22.62% |
|---|---|---|---|
| Sep 2023 | 8.14B | 1.46B | 17.97% |
| Dec 2023 | 8.05B | 350M | 4.35% |
| Mar 2024 | 7.36B | 1.04B | 14.21% |
| Dec 2023 | 8.05B | 350M | 4.35% |
|---|---|---|---|
| Mar 2024 | 7.36B | 1.04B | 14.21% |
| Sep 2025 | 11.51B | 4.44B | 38.63% |
| Dec 2025 | 11.13B | 2.59B | 23.34% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-02 | 0.937 | 1.1 |
|---|---|---|
| 2023-02-01 | 0.4819 | 0.61 |
| 2023-04-26 | 0.813 | 0.9 |
3.63%
Yield TTM
| Payout ratio | 95.58% |
|---|
| 2019 | 5.64% |
|---|---|
| 2020 | 7.42% |
| 2021 | 7.67% |
| 2022 | 5.93% |
| 2023 | 1.88% |
| Jun 2023 | 59461000000 | 47.30B | 79.55% |
|---|---|---|---|
| Sep 2023 | 60862000000 | 48.24B | 79.27% |
| Dec 2023 | 59005000000 | 46.21B | 78.32% |
| Mar 2024 | 58511000000 | 45.28B | 77.39% |
| Jun 2023 | 1.30B | -964M | 31M |
|---|---|---|---|
| Sep 2023 | 2.21B | -491M | -1.76B |
| Dec 2023 | 2.97B | 207M | -3.30B |
| Mar 2024 | 939M | -201M | -989M |
GSK alternative data
| Aug 2023 | 69,400 |
|---|---|
| Sep 2023 | 69,400 |
| Oct 2023 | 69,400 |
| Nov 2023 | 69,400 |
| Dec 2023 | 69,400 |
| Jan 2024 | 69,400 |
| Feb 2024 | 69,400 |
| Mar 2024 | 70,212 |
| Apr 2024 | 70,212 |
| May 2024 | 70,212 |
| Jun 2024 | 70,212 |
| Jul 2024 | 70,212 |
GSK other data
6.71%
+0.17%
of GSK is owned by hedge funds
864
-26
339.76M
+8.62M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 4 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 31 Jan 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 26 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Hal V. Barron F.A.C.C., M.D. (1963) Chief Scientific Officer, Pres of R&D and Director | $4,830,000 |
| Ms. Emma N. Walmsley (1970) Chief Executive Officer & Director | $3,730,000 |
Mr. Iain James Mackay (1962) Chief Financial Officer & Executive Director | $2,730,000 |
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
Merck: Don't Let Today's Bargain Opportunity Pass You By
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Amgen: Imdelltra Data And Q1 Results Impress
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Merck Proves Why It's Still A Top Pharma Pick
-
What's the price of GSK stock today?
One share of GSK stock can currently be purchased for approximately $39.31.
-
When is GSK's next earnings date?
Unfortunately, GSK's (GSK) next earnings date is currently unknown.
-
Does GSK pay dividends?
Yes, GSK pays dividends and its trailing 12-month yield is 3.63% with 96% payout ratio. The last GSK stock dividend of $0.52 was paid on 13 Jan 2022.
-
How much money does GSK make?
GSK has a market capitalization of 68.72B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.42% to 30.33B US dollars. GSK earned 4.93B US dollars in net income (profit) last year or $0.9 on an earnings per share basis.
-
What is GSK's stock symbol?
GSK plc is traded on the NYSE under the ticker symbol "GSK".
-
What is GSK's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of GSK?
Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are GSK's key executives?
GSK's management team includes the following people:
- Dr. Hal V. Barron F.A.C.C., M.D. Chief Scientific Officer, Pres of R&D and Director(age: 62, pay: $4,830,000)
- Ms. Emma N. Walmsley Chief Executive Officer & Director(age: 55, pay: $3,730,000)
- Mr. Iain James Mackay Chief Financial Officer & Executive Director(age: 63, pay: $2,730,000)
-
How many employees does GSK have?
As Jul 2024, GSK employs 70,212 workers.
-
When GSK went public?
GSK plc is publicly traded company for more then 45 years since IPO on 28 Mar 1980.
-
What is GSK's official website?
The official website for GSK is gsk.com.
-
How can i contact GSK?
GSK can be reached via phone at +44 20 8047 5000.
GSK company profile:
GSK plc
gsk.comExchange:
NYSE
Full time employees:
70,212
Industry:
Drug Manufacturers - General
Sector:
Healthcare
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
980 Great West Road
Brentford, TW8 9GS
Brentford, TW8 9GS
CIK: 0001131399
ISIN: US37733W2044
CUSIP: 37733W204
